Terms: = Liver cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
94 results:
1. Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma.
He L; Peng L; Wang L; Jiang X; Sun X; Li H; Lin T; Wu Z; Lin S
Biochem Biophys Res Commun; 2024 Jun; 714():149976. PubMed ID: 38677007
[TBL] [Abstract] [Full Text] [Related]
2. Integrated network toxicology, molecular docking, and in vivo experiments to elucidate molecular mechanism of aflatoxin B1 hepatotoxicity.
Ge B; Yan K; Sang R; Wang W; Liu X; Yu M; Liu X; Qiu Q; Zhang X
Ecotoxicol Environ Saf; 2024 Apr; 275():116278. PubMed ID: 38564860
[TBL] [Abstract] [Full Text] [Related]
3. USP21 deubiquitinates and stabilizes hsp90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma.
Xu X; Chen Y; Shao S; Wang J; Shan J; Wang Y; Wang Y; Chang J; Zhou T; Chen R; Liu S; Li C; Li C; Li X
Int J Biol Sci; 2024; 20(4):1492-1508. PubMed ID: 38385089
[TBL] [Abstract] [Full Text] [Related]
4. Tumor cell-derived LC3B
Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
[TBL] [Abstract] [Full Text] [Related]
5. Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888.
Kaplan Ö
Med Oncol; 2023 Oct; 40(11):318. PubMed ID: 37794195
[TBL] [Abstract] [Full Text] [Related]
6. hsp90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma.
Zhang J; Liu L; Li Y; Huang Y; Xiao S; Deng Z; Zheng Z; Li J; Liang M; Xie G; Chen X; Deng Y; Tan W; Su H; Wu G; Cai C; Chen X; Zou F
Neoplasia; 2023 Oct; 44():100935. PubMed ID: 37717471
[TBL] [Abstract] [Full Text] [Related]
7. USP14 governs CYP2E1 to promote nonalcoholic fatty liver disease through deubiquitination and stabilization of hsp90aa1.
Wei D; Tian X; Zhu L; Wang H; Sun C
Cell Death Dis; 2023 Aug; 14(8):566. PubMed ID: 37633951
[TBL] [Abstract] [Full Text] [Related]
8. An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and λ1 in HBV infection by promoting MAVS lysosomal degradation.
Zhang B; Han H; Zhao X; Li AN; Wang Y; Yuan W; Yang Z; Li MD
EBioMedicine; 2023 Aug; 94():104694. PubMed ID: 37442062
[TBL] [Abstract] [Full Text] [Related]
9. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating hsp90 mediated GPX4 ubiquitination and degradation.
Zhou C; Yu T; Zhu R; Lu J; Ouyang X; Zhang Z; Chen Q; Li J; Cui J; Jiang F; Jin KY; Sarapultsev A; Li F; Zhang G; Luo S; Hu D
Int J Biol Sci; 2023; 19(5):1471-1489. PubMed ID: 37056925
[TBL] [Abstract] [Full Text] [Related]
10. Triad pyrazole-thiazole-coumarin heterocyclic core effectively inhibit HSP and drive cancer cells to apoptosis.
Gümüş M; Koca İ; Sert Y; Dişli A; Yenilmez Tunoğlu EN; Tutar L; Tutar Y
J Biomol Struct Dyn; 2023; 41(23):14382-14397. PubMed ID: 36826447
[TBL] [Abstract] [Full Text] [Related]
11. Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases.
Chen Q; Li K; Rhodin KE; Masoud SJ; Lidsky ME; Cai J; Wei Q; Luo S; Zhao H
J Surg Oncol; 2023 May; 127(6):945-955. PubMed ID: 36807890
[TBL] [Abstract] [Full Text] [Related]
12. Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
Zhang F; Xu LD; Zhang Q; Wang A; Yu X; Liu S; Chen C; Wu S; Jin J; Lin A; Neculai D; Zhao B; Feng XH; Liang T; Xu P; Huang YW
J Hepatol; 2023 Apr; 78(4):704-716. PubMed ID: 36574921
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the potential targets of Sanshimao formula for hepatocellular carcinoma treatment by a method of network pharmacology combined with molecular biology.
Yu Q; Chen Z; Liu M; Meng Y; Li X; Li B; Du J
J Ethnopharmacol; 2022 Oct; 297():115531. PubMed ID: 35840058
[TBL] [Abstract] [Full Text] [Related]
14. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract] [Full Text] [Related]
15. Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule hsp90 inhibitor.
Hayat U; Elliott GT; Olszanski AJ; Altieri DC
Cancer Biol Ther; 2022 Dec; 23(1):117-126. PubMed ID: 35129069
[TBL] [Abstract] [Full Text] [Related]
16. GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma.
Huang R; Pan J; Zhang Y; Qin Q; Chao N; Huang T; Chen C; Zhao F; Luo G
J Healthc Eng; 2022; 2022():2518847. PubMed ID: 35070229
[TBL] [Abstract] [Full Text] [Related]
17. (20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the hsp90a-Cdc37 System in Human liver cancer Cells.
Chen C; Wang YS; Zhang ET; Li GA; Liu WY; Li Y; Jin YH
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884975
[TBL] [Abstract] [Full Text] [Related]
18. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC.
Zhang K; Li D; Zhou B; Liu J; Luo X; Wei R; Wang L; Hu X; Su Z; Lin H; Gao J; Shan H
Biomater Sci; 2021 Dec; 10(1):243-257. PubMed ID: 34846385
[TBL] [Abstract] [Full Text] [Related]
19. Impact of hsp90
Zhou W; Yang Y; Wang Z; Liu Y; Lari Najafi M
J Healthc Eng; 2021; 2021():6929971. PubMed ID: 34721827
[TBL] [Abstract] [Full Text] [Related]
20. Co-Expression of CD34, CD90, OV-6 and Cell-Surface Vimentin Defines cancer Stem Cells of Hepatoblastoma, Which Are Affected by hsp90 Inhibitor 17-AAG.
Lee-Theilen M; Hadhoud JR; Volante G; Fadini DD; Eichhorn J; Rolle U; Fiegel HC
Cells; 2021 Sep; 10(10):. PubMed ID: 34685577
[TBL] [Abstract] [Full Text] [Related]
[Next]
